Abstract:
Entamoeba histolytica is the etiological agent of amoebic dysentery and amoebic liver
abscess. Amoebiasis is one of the most common health problems in the developing
countries. Almost 10% people of the world are suffering from amoebiasis. Poverty,
ignorance, overcrowding, poor sanitation and malnutrition favor transmission and increased
disease burden. The main objective of the study was to find out the in vitro sensitivity of
different brands of Omidazole against clinical isolates of Entamoeba histolytica. Entamoeba
histolytica isolates was collected from the stool sample and cultured in different culture
medium. Different brands of Omidazole were prepared in different concentrations of 4.6,
2.3 ,1.15 , 0.575 , 0.287 and 0.143 JlM using the Di-methyl sulphoxide (DMSO) solvent and
incubated at 24 hours respectively. After incubation the isolates of viable Entamoeba
histolytica were calculated. Viable count of the Entamoeba histolytica in each concentration
of Omidazole (brands) were compared to the initial concentration and with the Omidazole
standard. After 24 hours of incubation concentration of 4.6 JlM showed very few amounts
of Entamoeba histoiytica. As the concentrations of Omidazole (brands and standard)
decreased (4.6, 2.3 ,1.15 , 0.575 , 0.287 and 0.143 J!M), after 48 hours of incubation the
viability of clinical isolates of Entamoeba histolytica increased These results showed that
Omidazole brands were effective to inhibit the growth of clinical isolates Entamoeba
histolytica.
Description:
This thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (B.Pharm) in East West University, Dhaka, Bangladesh.